Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07686731 · ClinicalTrials.gov registry record · Phase 4
Suvorexant 3 - PE-PC
A Phase 4 study, sponsored by Northern California Institute of Research and Education.
- Not yet
- Registry status
- Phase 4
- Development phase
- 142
- Enrollment target
NCT07686731 is a Phase 4 study that has not yet begun recruiting, run by Northern California Institute of Research and Education. The registered enrollment target is 142 participants.
The verdict
NCT07686731, a Phase 4 study, has not yet begun recruiting, sponsored by Northern California Institute of Research and Education.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 142 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if combining suvorexant (a sleep medication) with a shorter form of prolonged exposure therapy called PE-PC works to treat PTSD symptoms and improve sleep in Veterans and military personnel with PTSD and insomnia, with and without mild-to-moderate traumatic brain injury (TBI). The main questions it aims to answer are: Does suvorexant, when combined with PE-PC therapy, reduce PTSD symptoms more than PE-PC with a placebo (a look-alike substance that contains no drug)? Does suvorexant, when combined with PE-PC therapy, improve psychosocial and physical functioning more than PE-PC with a placebo? Researchers will compare PE-PC combined with suvorexant to PE-PC combined with a placebo to see if adding suvorexant improves PTSD symptoms, sleep, and overall functioning in Veterans. Participants will: Receive weekly PE-PC therapy sessions for 8 weeks Take suvorexant (10-20 mg) or a placebo each night during the 8-week treatment period. Complete repeated assessments of PTSD symptoms, sleep, and psychosocial and physical functioning throughout the study.
Interventions
- DRUG Placebo
- DRUG Suvorexant
- BEHAVIORAL Prolonged Exposure Therapy for Primary Care (PE-PC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2029-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07686731
The ClinicalTrials.gov registry entry for NCT07686731 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Institute of Research and Education, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07686731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07686731 about?
NCT07686731 is a clinical study titled "Suvorexant 3 - PE-PC". The goal of this clinical trial is to learn if combining suvorexant (a sleep medication) with a shorter form of prolonged exposure therapy called PE-PC works to treat PTSD symptoms and improve sleep in Veterans and military personnel with PTSD and insomnia, with and without mild-to-moderate traumati...
What is the current status of trial NCT07686731?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 142 participants. The study started on 2026-09-01. Estimated completion is 2029-08-30.
What interventions are being tested in trial NCT07686731?
The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG), Prolonged Exposure Therapy for Primary Care (PE-PC) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07686731?
This trial is sponsored by Northern California Institute of Research and Education, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.